News

January 17, 2020

Large Study Finds No Strong Link Between Talc Powder and Ovarian Cancer Risk

News

After decades of conflicting evidence about the possible link between talc powder in the genital area and ovarian cancer, the largest study conducted to date has found no strong ... Read more

January 14, 2020January 15, 2020

FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status

News

The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination ... Read more

January 10, 2020January 10, 2020

Anixa and Moffitt Seek to Improve Potency of CAR T-cell Candidate for Ovarian Cancer

News

Anixa Biosciences and Moffitt Cancer Center are seeking to develop a more potent version of their immunotherapy candidate for ovarian cancer, based on chimeric antigen receptor (CAR) T-cell technology, ... Read more

January 8, 2020

Second Surgery for Recurrent Ovarian Cancer Does Not Improve Survival, Phase 3 Trial Shows

News

A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first ... Read more

December 20, 2019

Trial Seeks Participants to Study AVB-500 Plus Imfinzi in Platinum-resistant Ovarian Cancers

News

Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant ... Read more

December 17, 2019December 18, 2019

Pivotal Trial of Mirvetuximab Soravtansine in Advanced Ovarian Cancer Levels Likely in 2020

News

ImmunoGen is planning to open an open-label, pivotal clinical trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer patients with high levels of the folate receptor alpha (FRα) protein early next ... Read more

December 13, 2019December 13, 2019

NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers

News

After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) ... Read more

December 12, 2019January 6, 2020

Thin Mesh Loaded with CAR T-cells Seen to Shrink Inoperable Ovarian Tumors in Mice

News

Implantable devices made of a thin metallic mesh loaded with cancer-fighting immune cells are able to shrink inoperable ovarian tumors in mice, offering a potential way to boost the ... Read more

December 11, 2019

Cancer Research Teams Working to Identify Early Biomarkers of Ovarian Cancer

News

With a $544,360 developmental grant from the U.S. Department of Defense (DoD), four research teams are joining efforts to identify biomarkers of ovarian cancer with a goal of detecting ... Read more

December 6, 2019December 6, 2019

Sutro’s Investigational Antibody-Drug Conjugate Shows Promise in Advanced Ovarian Cancer Phase 1 Trial

News

STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase ... Read more

Pin It on Pinterest